Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence

BACKGROUND: Use of hydroxychloroquine (HCQ) is common in patients with lupus erythematosus. Long-term use (ie, ≥5 years) and high-dose HCQ (ie, >5 mg/kg/day) are both risk factors for developing HCQ retinopathy. Advances in our understanding of HCQ retinopathy have led to changes in the recommend...

Descripción completa

Detalles Bibliográficos
Autores principales: Osmani, Zgjim, Schrama, Thijs J, Zacouris-Verweij, Wendy, Andersen, Jeanette, Frankel, Susan, Bultink, Irene E M, Cornet, Alain, van Vollenhoven, Ronald F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Epidemiology and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021889/
https://www.ncbi.nlm.nih.gov/pubmed/33795484
http://dx.doi.org/10.1136/lupus-2021-000478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021889/
https://www.ncbi.nlm.nih.gov/pubmed/33795484
http://dx.doi.org/10.1136/lupus-2021-000478

Ejemplares similares